2026 funding calls- Cycle2

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today a funding solicitation with four distinct product themes:

• Direct-acting therapeutics for infections caused by Gram-negative bacteria
• CARB-X Novel Chemistry for AMR Challenge – target-based therapeutics
• Non-vaccine approaches to prevent neonatal sepsis
• Diagnostics for neonatal sepsis

Funding: varies according to project type and phase

Duration: No fixed limit

Research Authority due date: 16.11.26